163 results about "Angiopathy" patented technology

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

The invention discloses a cardiovascular lesion classification method and system based on data analysis, relates to the technical field of cardiovascular lesion classification, and aims to solve the problem of poor accuracy when cardiovascular lesions of patients are classified. According to the method, multi-dimensional features are extracted for images, time sequence signals and structured data, and fusion is realized through data layer clinical association screening, feature layer composite vector recombination and decision layer weight summation. The method breaks through the limitation of a single data dimension, enables a classification result to be more fit with a pathological mechanism, remarkably improves the recognition precision of complex lesions and complications, guarantees the reliability of hardware through precise configuration of equipment and multi-dimensional detection, customizes a preprocessing process according to the data type, and associates multi-source data through a patient ID and a timestamp, thereby improving the recognition precision of the complex lesions and complications. The problems that equipment is disordered and data formats are different in a traditional process are solved.

The illustrative methods and systems facilitate one or more dynamic analyses that can characterize and identify synchronization between acquired cardiac signals and photoplethysmography signals to predict / estimate the presence, location, and / or severity of abnormal cardiovascular conditions or diseases, including, for example, but not limited to, coronary artery disease, heart failure (including but not limited to indicators of disease or condition, such as abnormal left ventricular end-diastolic pressure disease), and pulmonary hypertension. In some embodiments, statistical properties of the synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical properties of a histogram of synchronization between the cardiac signal and the photoplethysmography signal are evaluated. In some embodiments, statistical and / or geometric properties of a Poincare map of synchronization between the cardiac signal and the photoplethysmography signal are evaluated.

Disclosed are methods, systems, and a device for automated interpretation of cardiac magnetic resonance imaging. A method includes acquiring a sequence of radiographic images of a heart, including at least one of: a cine MRI, a late gadolinium enhancement, a T1 mapping, a T2 mapping, a perfusion imaging, a flow quantification, a dark blood imaging, a real-time imaging, a magnetic resonance spectroscopy, or a parametric mapping sequence. Further, the method processes the sequence of radiographic images using one or more machine learning models. Additionally, the method generates a diagnostic prediction using the machine learning models. The diagnostic prediction is a screening prediction of a cardiac anatomy, a diagnostic suggestion of a cardiovascular condition, a quantitative assessment of a cardiac function parameter, a structured radiographic report, a natural language summary, or a diagnostic rationale. A diagnostic prediction is output to an electronic system.

Disclosed are methods, systems, and a device for automated interpretation of cardiac magnetic resonance imaging. A method includes acquiring a sequence of radiographic images of a heart, including at least one of: a cine MRI, a late gadolinium enhancement, a T1 mapping, a T2 mapping, a perfusion imaging, a flow quantification, a dark blood imaging, a real-time imaging, a magnetic resonance spectroscopy, or a parametric mapping sequence. Further, the method processes the sequence of radiographic images using one or more machine learning models. Additionally, the method generates a diagnostic prediction using the machine learning models. The diagnostic prediction is a screening prediction of a cardiac anatomy, a diagnostic suggestion of a cardiovascular condition, a quantitative assessment of a cardiac function parameter, a structured radiographic report, a natural language summary, or a diagnostic rationale. A diagnostic prediction is output to an electronic system.

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation and application thereof, and belongs to the technical field of chronic obstructive pulmonary disease medicines. The traditional Chinese medicine composition consists of a qi tonifying component, a blood activating component and a phlegm reducing component, or consists of the qi tonifying component and the blood activating component, or consists of the qi tonifying component and the phlegm reducing component, wherein the qi-tonifying component is selected from any one or a combination of more of ginsenoside Rg1, ginsenoside Rb1, astragaloside and schizandrin; the blood activating component is selected from any one or combination of more of ligustrazine and ferulic acid; the phlegm reducing component is selected from any one or combination of more of glucosinolate and quercetin. The compatibility and combination of the medicines have obvious effects in the aspects of improving lung inflammatory response and inhibiting pathological remodeling of pulmonary blood vessels.

The present disclosure relates to methods of treating, preventing or managing cardiovascular and / or metabolic disorders selected from the group consisting of hypercholesteremia, dyslipidemia, hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes and obesity in a human subject in need thereof by administering a human FGF21 protein variant.

The invention relates to compounds of Formula (I), or pharmaceutically acceptable salts thereof; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful as therapeutic and / or preventative agents to treat diseases that involve abnormal amino acid metabolism, amino acid transport and / or amino acid level, cardiovascular disorders, renal disorders, or metabolic diseases, such as phenylketonuria, NASH, NAFLD, heart failure, chronic kidney disease, and related disorders.

The present invention relates to compounds of formula (I), and stereoisomers, tautomers, N- oxides, and pharmaceutically acceptable salts thereof that are useful for modulating, preferably inhibiting three-prime repair exonuclease (TREX1). The present invention further relates to compounds of formula (I) for use as a medicament and to pharmaceutical compositions comprising said compounds. Further, the present invention relates to compounds of formula (I) and pharmaceutical compositions comprising said compounds for use in the treatment of cancer, such as breast, small cell lung cancer and colorectal cancer, in particular cancers with chromosomal instability, TREX1-mediated autoimmune diseases, inflammatory myocarditis, Aicardi-Goutières syndrome (AGS), familial chilblain lupus (FCL), systemic lupus erythematosus (SLE) and retinal vasculopathy with cerebral leukodystrophy (RVCL).

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD, NASH, or MASH, or drug induced liver injury (DILI).

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The invention relates to the technical field of cardiovascular disease health risk assessment and management, and discloses a cardiovascular patient group health assessment system based on diet and individual characteristics, which comprises a data acquisition module, an analysis and prediction module and a health assessment module. According to the cardiovascular patient group health assessment system based on diet and individual characteristics, a data acquisition module acquires a user data set, a data preprocessing unit identifies the user data set, a risk proportion unit calculates a disease risk ratio Hbfx, and a variable prediction unit calculates a disease prediction data set Fbyc; the health assessment module calculates a comprehensive influence data set Zhyx and comprehensively assesses the influence of significant variables of a user on CVD risks, analysis and assessment are more comprehensive and highly targeted, the health assessment module compares a reference data set according to the comprehensive influence data set Zhyx and judges and assesses corresponding scores, and the effect of early intervention and treatment of cardiovascular diseases is better.

This invention relates to a method and system for cardiovascular disease risk assessment based on machine learning models. By utilizing machine learning models to focus on predicting the risk of heart failure, it accurately distinguishes between healthy individuals and those with cardiovascular disease, emphasizing the differentiation of heart failure and other common cardiovascular diseases, and deeply exploring diagnostic indicators, thus opening new avenues for cardiovascular diagnosis and treatment. It hierarchically utilizes features closely related to blood cells, blood lipids, and blood glucose, and constructs predictive models using multiple machine learning models, laying a solid foundation for further in-depth research. This invention fully utilizes diagnostic indicators and multiple machine learning models, making full use of the predictive results and differentiated characteristics of different machine learning models to achieve efficient and accurate 5-category risk assessment.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The invention discloses a nattokinase product for preventing and / or treating atherosclerosis and application of the nattokinase product. Cardiovascular diseases become the primary reason of human death, and the vascular plaque problem caused by atherosclerosis is always a difficult problem to be solved urgently. Blood vessel stenosis caused by plaques is a main cause of cerebral arterial thrombosis, and traditional medicines and operations face the problems of low compliance, side effect risk, indication limitation and the like. The invention provides nattokinase or a product thereof for high-risk groups with cardiovascular diseases, and the nattokinase or the product thereof is preferably in a non-drug form. As a precise nutrition intervention means, nattokinase is effective in plaque progress inhibition, unique in effect, safe to eat, convenient, easy to implement and wide in applicable crowd. The invention provides a new thought and method for management of vascular plaques and prevention and treatment of cardiovascular diseases.

The present invention relates to the technical field of limb function exercise, in particular to a limb function exercise device for use after elderly vascular diseases, including a bottom plate, one end of the top surface of the bottom plate is fixedly provided with a seat cushion, and it is characterized in that: two sliding grooves are opened at the other end of the top surface of the bottom plate, a sliding plate is arranged above the two sliding grooves, both sides of the two sliding plates are slidably connected with guide rails, guide grooves are opened on the guide rails, and all the guide rails are fixedly connected with the top of the bottom plate; a pedal is hinged on the top surface of the sliding plate, and a first torsion spring is sleeved on the hinge shaft of the pedal and the sliding plate; during the process that a vascular disease patient pushes the pedal to move to the side away from the seat cushion, relative movement occurs between the lower leg of the vascular disease patient and the extrusion rod, so that the extrusion rod can push the blood accumulated in the veins on both sides of the lower leg of the vascular disease patient to flow back towards the thigh direction, emptying the veins. By reversely pushing the blood on both sides of the lower leg of the vascular disease patient, it is beneficial to dredge the meridians of the lower leg, promote blood circulation, and play a role in promoting blood circulation and removing blood stasis.

The invention provides an application of Exifenone in preparation of a medicine for treating diabetic retinopathy, the Exifenone can be combined near a K412 lactic acid modification site of HDAC1, so that the lactic acid modification of the K412 site of the HDAC1 is specifically inhibited, the deacetylation activity of the HDAC1 to H3K56 is enhanced, the transcriptional activation of VEGFA (vascular endothelial growth factor A) mediated by H3K56ac and pathological angiogenesis are inhibited, and the effect of treating diabetic retinopathy is achieved. Further, vascular pathological injury caused by diabetic retinopathy is improved. The application provides a new target and a candidate drug for clinical treatment of diabetic retinopathy. The research result of the application provides experimental evidence for the epoxybenzophenone to be used for clinical specific treatment of diabetic retinopathy.

The application belongs to the technical field of biomedicine, and particularly relates to a construction system of a cerebral amyloid angiopathy recognition model, a storage medium and a kit. Based on plasma proteomic data of cerebral amyloid angiopathy patients and normal old controls, six key protein markers closely related to cerebral amyloid angiopathy are screened out. The application also provides a model for recognizing cerebral amyloid angiopathy based on a combination of six plasma protein biomarkers. The model shows excellent performance in multiple independent data sets, can accurately distinguish cerebral amyloid angiopathy patients from normal old controls, and further distinguish cerebral amyloid angiopathy patients with high-risk cerebral hemorrhage risk from those with low-risk cerebral hemorrhage risk. The application provides a new tool for early diagnosis and hemorrhage risk assessment of cerebral amyloid angiopathy.

The invention relates to the technical field of compression hemostasis, and particularly discloses a cardiovascular patient postoperative compression hemostasis auxiliary device which comprises a compression hemostasis body and a winding mechanism, and the winding mechanism is arranged on one side of a compression cover to wind a first binding belt and a second binding belt; the detection mechanism is arranged in the winding mechanism and is used for monitoring the puncture point of the patient; the salt adding mechanism is arranged in the sealing cover and is used for adding salt into the compressed salt bag. A rolling column on the second binding belt is inserted into the rolling mechanism, the first binding belt and the second binding belt are gradually rolled through the rolling mechanism, so that pressure is applied to the pressing cover to press a puncture point, and meanwhile whether the pressed puncture point bleeding or not can be detected through the detection mechanism; whether the patient is bleeding or not can be displayed to medical staff through the test strip.

Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating cerebrovascular disease and a preparation method thereof. The traditional Chinese medicine composition for treating cerebrovascular disease comprises the following raw materials in parts by weight: 19-24 parts of chuanxiong, 15-20 parts of gastrodia, 8-14 parts of kudzu vine tea, 11-17 parts of San Ye Qing Teng, 3-9 parts of hibiscus flower, 7-12 parts of polygala, and 2-5 parts of licorice. The chuanxiong in the composition has the effects of activating blood and regulating qi, and the gastrodia has the effects of calming wind and stopping convulsion, and both of them are used as monarch drugs. The kudzu vine tea and San Ye Qing Teng are used as minister drugs, the kudzu vine tea has the effect of resolving and dredging collaterals, and the San Ye Qing Teng has the effect of dispelling wind and relieving pain. The hibiscus flower and polygala are both used as auxiliary drugs, and the licorice is used as a guide drug. The licorice can not only harmonize all drugs, but also warm the center and promote drug absorption. The traditional Chinese medicine composition has the effects of activating blood and resolving stasis, dredging collaterals and relieving pain, and soothing the nerves and helping sleep. The composition has good therapeutic effects on stroke and apoplexy.

Provided for are compositions and methods for treating amyloid related imaging abnormalities (ARIA) with selective Janus kinase (JAK) inhibitors in Alzheimer's disease (AD) patients or patients with other with neurodegenerative disease or cerebral amyloid angiopathy-related inflammation (CAAri) undergoing anti-amyloid therapy, including anti- amyloid antibody therapies. Particularly useful are JAK inhibitors selective against JAK1 and tyrosine kinase 2 (TYK2).

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

This invention provides a deep learning-based intelligent analysis method for cardiovascular medical images, comprising the following steps: S1, heterogeneous data fusion and acquisition of multimodal medical images and physiological signals; S2, intelligent extraction and quantitative analysis of vascular structural features based on deep learning; S3, hemodynamic parameter modeling and risk region segmentation based on fused structural features; S4, texture feature mining and intelligent identification of lesion types in high-risk areas; S5, cardiovascular disease risk stratification prediction based on multi-dimensional feature fusion; S6, federated learning optimization and closed-loop update of the model. This invention's deep learning-based intelligent analysis method for cardiovascular medical images achieves, for the first time, heterogeneous fusion of medical images, millimeter-wave radar-PPG physiological signals, and clinical molecular data, and achieves precise spatiotemporal alignment through GPS-controlled crystal oscillators, overcoming the limitations of single image analysis and providing a more comprehensive feature foundation for subsequent feature extraction and risk prediction.

The invention discloses a traditional Chinese medicine preparation for preventing postoperative vascular stenosis and occlusion and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine preparation for preventing postoperative vascular stenosis and occlusion is prepared from a multi-layer assembled amphiphilic polymer, a traditional Chinese medicine compound extract and curcumin, the multi-layer assembled amphiphilic polymer is used as a carrier, curcumin and a traditional Chinese medicine compound extract are effectively loaded in an encapsulation and adsorption mode, the drug loading capacity is improved, the drug concentration of a drug at a vascular focus part can be remarkably improved in a long-circulation, targeting and pH response release precise delivery mode, the bioavailability of the drug is improved, and the bioavailability of the drug is improved. Meanwhile, the precise delivery mode can also reduce the distribution of the medicine in normal tissues, so that the toxic and side effects are reduced, and the treatment safety is improved.

The present invention relates to a solid pharmaceutical dosage form for oral administration, comprising (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32, 5-dioxo-14-(trifluoromethyl)-32H-6-aza-3 (4, 1)-pyridine-1 (1)-[1, 2, 3] triazole-2 (1, 2), 7 (1)-dibenzaheptaphane-74-carboxamide (active ingredient (I)), and a pharmaceutically acceptable salt thereof. The active ingredient (I) is present in amorphous form and is released immediately from a solid pharmaceutical dosage form for oral administration, and to a method for the production thereof, to the use thereof as a medicament, and to the use thereof for the treatment and / or prophylaxis of diseases, in particular diseases, such as diseases. Use in particular for cardiovascular disorders, preferably thrombotic or thromboembolic disorders and oedema and ocular disorders

Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins.

A chemically modified polynucleotide encoding a fusion protein, wherein the chemically modified polynucleotide comprises a sequence of SEQ ID NO: 701 is claimed wherein the fusion comprises a Cas9 nickase and and deaminase, such as an adenosine deamnase TadA. and which further comprises a protospacer found on a gene encoding Angiopoietin-like 3 protein (ANGPTL3). The chemical modifications may include phosphorothioate linkages and 2'-O-methyl modfied nucleosides. Use of such fusions in treating cardiovascular conditions is further claimed. [Figure 3]

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain H-APPAMP compounds (referred to herein as “H-APPAMP compounds”) that, inter alia, inhibit cyclin-dependent protein kinases (CDKs), especially CDK12 and / or CDK13, and are selective, for example, for CDK12 and / or CDK13 as compared to CDK7. In addition to selectively inhibiting CDK12 and / or CDK13, the compounds also act as selective Cyclin K degraders thereby removing the key signaling mechanism required for CDK12 and / or CDK13 activation; this confers additional cellular potency and selectivity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK, especially CDK12 and / or CDK13; and to treat disorders including: disorders that are associated with CDK, especially CDK12 and / or CDK13; disorders that result from an inappropriate activity of a CDK, especially CDK12 and / or CDK13; disorders that are associated with CDK mutation, especially CDK12 and / or CDK13 mutation; disorders that are associated with CDK overexpression, especially CDK12 and / or CDK13 overexpression; disorders that are associated with upstream pathway activation of CDK, especially CDK12 and / or CDK13; disorders that are ameliorated by the inhibition of CDK, especially CDK12 and / or CDK13; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; cardiovascular disorders (including atherosclerosis); autoimmune disorders (including rheumatoid arthritis); and disorders caused by dysfunction of translation in cells (including muscular dystrophy). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti estrogen, an anti-androgen, a Her2 blocker, a cytotoxic chemotherapeutic agent, an agent stimulating the immune system, a checkpoint inhibitor, a DNA repair inhibitor, etc.